We tested the hypothesis that pirfenidone might be beneficial in SSc-ILD due to its anti-inflammatory and antifibrotic effects, by applying a mouse model overexpressing the AP-1 transcription factor Fos-related antigen-2 (Fra-2 transgene) [17]. Here, FOSL2 is linked to systemic sclerosis.